Can metformin be safely continued or started during pregnancy in a woman with pre‑existing type 2 diabetes mellitus or polycystic ovary syndrome (PCOS), and is it appropriate for gestational diabetes when diet and exercise fail, assuming adequate renal function (creatinine clearance ≥ 60 mL/min) and a maximum dose of 2,500 mg per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Metformin in Pregnancy

In pregnant women with pre-existing type 2 diabetes already on insulin, metformin should NOT be routinely added, while for gestational diabetes, metformin can be used as an alternative to insulin when diet/exercise fail, though insulin remains preferred. For PCOS, metformin may be continued through pregnancy primarily to reduce preterm birth and late miscarriage risk, but there is no evidence-based need to continue it solely for preventing gestational diabetes or miscarriage 1, 2.

Pre-existing Type 2 Diabetes

The 2025 Endocrine Society/European Society of Endocrinology joint guideline explicitly recommends AGAINST routine addition of metformin to insulin in pregnant individuals with type 2 diabetes already on insulin therapy (conditional recommendation, very low certainty evidence) 1.

Key considerations:

  • Women with type 2 diabetes in pregnancy have more severe insulin deficiency and insulin resistance than those with gestational diabetes, typically requiring insulin for optimal glycemic control 1
  • Metformin is NOT a substitute for insulin in type 2 diabetes during pregnancy 1
  • While metformin may reduce large-for-gestational-age infants and gestational weight gain, concerns exist about fetal growth restriction and long-term offspring effects 1
  • RCTs comparing insulin alone versus insulin plus metformin showed no differences in composite neonatal outcomes, but the metformin groups had smaller birth weights and one study showed doubling of small-for-gestational-age neonates 2

Gestational Diabetes Mellitus

Metformin can be used as an alternative to insulin for gestational diabetes when diet and exercise fail, though insulin remains the preferred first-line pharmacologic agent 2.

Benefits in GDM:

  • Lower risk of neonatal hypoglycemia compared to insulin 2
  • Less maternal weight gain 2
  • More acceptable to patients due to oral route, low cost, ease of administration, and low hypoglycemia risk 1

Limitations:

  • Treatment monotherapy failure occurs in 14-46% of individuals, requiring insulin supplementation 2
  • Does not reduce risk of developing GDM when used prophylactically in high-risk women with obesity, PCOS, or insulin resistance 2

Polycystic Ovary Syndrome (PCOS)

For women with PCOS who become pregnant, metformin may be continued primarily to reduce the risk of late miscarriage and preterm birth, but there is no evidence-based need to continue it for preventing gestational diabetes or early miscarriage 2.

Evidence in PCOS pregnancies:

  • May reduce early pregnancy loss, miscarriage, and preterm birth 3, 4
  • Does NOT prevent gestational diabetes or spontaneous abortion when used for ovulation induction 2
  • No benefit demonstrated for preventing GDM in meta-analysis of 11 RCTs 2

Critical Safety Considerations

Placental Transfer and Fetal Exposure

Metformin readily crosses the placenta, achieving fetal levels equal to or higher than maternal levels due to high OCT3 transporter expression in second and third trimester placenta 1, 2. It concentrates 1000-fold in fetal and placental mitochondria and has pleiotropic effects including AMPK activation and mitochondrial complex 1 inhibition 1.

Long-term Offspring Concerns

The most significant concern is potential long-term metabolic programming effects on offspring:

  • MiG TOFU study: 9-year-old offspring exposed to metformin for GDM treatment (Auckland cohort) were heavier with higher waist-to-height ratio and waist circumference compared to insulin-exposed offspring 2
  • PCOS offspring studies: 4-year follow-up showed higher BMI and increased obesity; 5-10 year follow-up demonstrated higher BMI, weight-to-height ratios, waist circumferences, and borderline increased fat mass 2
  • Meta-analysis: Metformin exposure resulted in smaller neonates with acceleration of postnatal growth, resulting in higher BMI in childhood 2
  • MiTy Kids trial: No differences in anthropometrics at 24 months follow-up 2

Teratogenicity

Metformin crosses the placenta poorly in the first trimester and does NOT increase the risk of major malformations 1, 5.

FDA Labeling Guidance

The FDA label states metformin is "not for people with type 1 diabetes" or "diabetic ketoacidosis" 5. Regarding pregnancy:

  • Advises discussing with healthcare provider about "best way to control blood sugar while pregnant" 5
  • States "It is not known if metformin hydrochloride tablets will harm your unborn baby" 5
  • Maximum dose: 2,550 mg per day in divided doses 5

Renal Function Requirements

Metformin is contraindicated with eGFR <30 mL/min/1.73 m² 5. Initiation is not recommended with eGFR 30-45 mL/min/1.73 m². If eGFR falls below 45 mL/min/1.73 m² during therapy, assess benefit-risk and discontinue if it falls below 30 mL/min/1.73 m² 5.

Clinical Algorithm

For Type 2 Diabetes:

  1. Use insulin as primary therapy
  2. Do NOT routinely add metformin to insulin regimen
  3. If metformin was used pre-pregnancy, consider discontinuation given lack of benefit and offspring concerns

For Gestational Diabetes:

  1. Start with diet and exercise
  2. If inadequate control, insulin is preferred
  3. Metformin is acceptable alternative if patient preference, cost, or adherence favor oral therapy
  4. Monitor for treatment failure (14-46% rate) requiring insulin supplementation
  5. Counsel about potential long-term offspring metabolic effects

For PCOS:

  1. If metformin used pre-pregnancy for metabolic/fertility reasons, may continue to reduce preterm birth/late miscarriage risk
  2. Do NOT continue solely for GDM or early miscarriage prevention (no proven benefit)
  3. Counsel about uncertain long-term offspring effects

Common Pitfalls

  • Assuming metformin is equivalent to insulin in type 2 diabetes pregnancy: It is not—insulin deficiency is too severe 1
  • Using metformin prophylactically to prevent GDM: No evidence of benefit 2
  • Ignoring the 14-46% failure rate in GDM: Close monitoring and insulin backup plan essential 2
  • Failing to counsel about long-term offspring effects: Evidence is mixed but concerning for childhood adiposity 2
  • Not checking renal function: Contraindicated with eGFR <30 mL/min/1.73 m² 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.